Marina Biotech, Inc.  

(Public, OTCMKTS:MRNA)   Watch this stock  
Find more results for NASDAQ:NSTK
0.262
+0.012 (4.80%)
May 27 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.24 - 0.26
52 week 0.12 - 0.58
Open 0.24
Vol / Avg. 24,308.00/255,574.00
Mkt cap 8.12M
P/E 1.80
Div/yield     -
EPS 0.15
Shares 29.76M
Beta 0.28
Inst. own 0%
Aug 11, 2016
Q2 2016 Marina Biotech Inc Earnings Release (Estimated) Add to calendar
May 17, 2016
Q1 2016 Marina Biotech Inc Earnings Release
Mar 31, 2016
Q4 2015 Marina Biotech Inc Earnings Release
  

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 426.80% 490.74%
Operating margin -400.40% -583.97%
EBITD margin - -586.62%
Return on average assets 57.94% 39.70%
Return on average equity 489.39% -
Employees 1 -
CDP Score - -

Address

3830 Monte Villa Pkwy
BOTHELL, WA 98021-7266
United States - Map
+1-425-9083600 (Phone)
+1-302-6745266 (Fax)

Website links

Description

Marina Biotech, Inc. is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases. The Company's pipeline is orphan disease focused and includes a clinical program in Familial Adenomatous Polyposis (FAP) and preclinical programs in type 1 myotonic dystrophy (DM1) and Duchenne's muscular dystrophy (DMD). Its partners, ProNAi Therapeutics, Inc. (ProNAi) and Mirna Therapeutics, Inc. (Mirna) are focused on oncology and have clinical programs in recurrent or refractory non-Hodgkin's lymphoma and unresectable primary liver cancer or solid cancers with liver involvement, respectively. The Company has two liposomal-based delivery platforms. The first platform, SMARTICLES, defines a class of liposomes that are charge-reversible particles allowing delivery of active substance. The second platform utilizes amino-based liposomal delivery technology.

Officers and directors

J. Michael French Chairman of the Board, President, Chief Executive Officer
Age: 55
Daniel E. Geffken CPA Interim Chief Financial Officer
Age: 58
Stefan D. Loren Ph.D. Lead Independent Director
Age: 51
Philip C. Ranker Director
Age: 54
Trading Activity - Yahoo Finance
Joseph W. Ramelli Independent Director
Age: 46
Donald A. Williams Independent Director
Age: 56